

ACT-NOW: Anti  
cancer therapy  
nationally  
organized  
workstreams

# What we will cover today

- Intro to ACT-NOW Project
- Regimen library
- Why we need to align regimens
- Example of data

## Key messages:

- The ACT-NOW regimen library is a useful clinical resource.
- Aligning practice creates consistent care across NZ.
- Aligning to regimens helps data collection to drive quality improvement.

# What is ACT-NOW

## **Project purpose:**

To deliver key components to address existing information gaps in monitoring SACT variation, quality, access and performance in New Zealand.

Standardise data definitions

Establish what are SACT measures

Create a centralised data repository

# Why ACT-NOW

## What is prescribed:

- Regimen library

## What happens during treatment:

- ACT-NOW data standard

## Patient outcomes:

- Other national data sets

Once people are in the MO service, is there a difference in survival?

How has the new medicines implementation changed cancer outcomes for patients

How many lines of treatment are people receiving?

How much treatment are we delivering?  
Are we stopping early?

What is the hospital admission rate for different chemo regimens?

What do prescribing patterns of care look like?

What proportion of people with cancer are accessing SACT?

Does where you live affect the treatment you receive?

What are the resource requirements for different regimens?

# Systemic Anti- Cancer Therapy Regimen Library

Te Aho o Te Kahu & New  
Zealand formulary  
collaboration

# The regimen library

Standardised  
naming



NZ practice  
centric



Overview of  
prescribing



# Why do we need a regimen library

**National Non-Admitted Patient Collection (NNPAC)**

**Pharmaceutical dispensings (PHARMS)**



## Why & How

CRC Metastatic - pembrolizumab Q3W [flat dosing]

CRC Metastatic - pembrolizumab Q6W [flat dosing]

GU PROS Metastatic - pembrolizumab [flat dose]

GU Renal cell Adjuvant - pembrolizumab Q3W [flat dosing]

GU Renal cell Metastatic - aXITinib and pembrolizumab Q3W [flat dosing]

GU Renal cell Metastatic - aXITinib and pembrolizumab Q6W [flat dosing]

GU Renal cell Metastatic - leNVatinib and pembrolizumab Q3W [flat dosing]

GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing]

GU Renal cell Metastatic - pembrolizumab Q3W [flat dosing] and ipilimumab

GU Renal cell Metastatic - pembrolizumab Q6W [flat dosing]

GU URO Advanced - enfortumab vedotin and pembrolizumab

GU URO Advanced - pembrolizumab Q3W [flat dosing]

GU URO Advanced - pembrolizumab Q6W [flat dosing]

GU URO Metastatic - PAClitaxel Q1W and pembrolizumab Q3W [flat dosing]

GYN - pembrolizumab Q3W [flat dosing]

GYN - pembrolizumab Q3W [weight based dosing]

GYN - pembrolizumab Q6W [flat dosing]

GYN CX Advanced - cARBOplatin, PACLitaxel and pembrolizumab

GYN CX Advanced - cARBOplatin, PACLitaxel, beVACizumab and pembrolizumab

GYN CX Advanced - ciSplatin, PACLitaxel and pembrolizumab

GYN CX Advanced - ciSplatin, PACLitaxel, beVACizumab and pembrolizumab

GYN END Advanced - cARBOplatin, PACLitaxel and pembrolizumab

GYN END Advanced - leNVatinib and pembrolizumab Q3W [flat dosing]

HN SQCC Metastatic - cARBOplatin, fluorouracil and pembrolizumab

# What is an ACT-NOW regimen

## Mandatory

Indication

Drug(s)

Dose

Route

Frequency (in a cycle)

Cycle length

## Inclusion criteria:

- Is available in New Zealand
- Is being used by a medical oncologist or haematologist
- Supported by robust clinical evidence

## Recommended

Number of cycles\*

Duration of infusion


Supportive care



# How do regimens get created



Tumour stream working groups



New Zealand formulary  
pharmacist technical review



Clinical sign off

The New Zealand  
Formulary


**Request a new regimen**

Terms of Use, Guidance and Disclaimers


What's new

Subscribe to monthly updates

# Regimen library : Regimens



Accessed by NZF



Arranged by Cancer type and treatment intent



Website:  
<https://srl.org.nz/regimens>

## The risky LIVE DEMO



# [If demo fails] SRL home page



Cancer Type

—

Medical Oncology

Breast

Central Nervous System

Colorectal

Gynaecological

Head and Neck

Neuroendocrine

Respiratory

Sarcoma

Skin Cancer

Upper Gastrointestinal

Urogenital

Haematology

Haematopoietic Stem Cell Transplant

Leukaemias

Lymphoma

Plasma Cell Neoplasms

Request a new regimen

Terms of Use, Guidance and Disclaimers

What's new

Subscribe to monthly updates

Resources

Abbreviations

Regimen Review Workshops

## Systemic Anti-Cancer Therapy Regimen Library

### Welcome to the Systemic Anti-Cancer Therapy Regimen Library (SACT Regimen Library or SRL).

The Anti-Cancer Therapy – Nationally Organised Workstreams (ACT-NOW) programme is developing a detailed database of information on patients receiving systemic therapy across New Zealand. ACT-NOW works with the medical oncology, haematology, pharmacist, and nursing communities to identify and reduce variation, enhance equity of access, and support resource planning. The SACT Regimen Library (SRL) is a key component of ACT-NOW.

SRL is a national database of systemic anti-cancer therapy regimen definitions that have been developed and endorsed by the New Zealand clinical community. The objective of the SRL is to identify the range of systemic therapy regimens in use and give each a clear name. Previously, cancer centres have used different names for similar regimens, and this has limited the ability to compare outcomes and improve care. Clinicians have agreed a standard naming convention as part of working together to better understand how systemic therapy is being delivered in New Zealand and how we can improve treatment and outcomes for people with cancer.

[More information](#) [FAQ](#) [Glossary](#) [Terms of Use, Guidance and Disclaimers](#) [What's new](#) [Subscribe to monthly updates](#)

### Cancer Type

#### Medical Oncology

[Breast](#)  
[Central Nervous System](#)  
[Colorectal](#)  
[Gynaecological](#)  
[Head and Neck](#)  
[Neuroendocrine](#)  
[Respiratory](#)  
[Sarcoma](#)  
[Skin Cancer](#)  
[Upper Gastrointestinal](#)  
[Urogenital](#)




#### Haematology

[Haematopoietic Stem Cell Transplant](#)  
[Leukaemias](#)  
[Lymphoma](#)  
[Plasma Cell Neoplasms](#)


# [If demo fails] SRL regimen

## Metastatic Regimens

### Published

Name 	Version 	Date 
<a href="#">BR Advanced/Metastatic - abemaciclib</a>	1.0.0	24/07/2024
<a href="#">BR Metastatic - Abraxane [PAClitaxel nanoparticle albumin bound] [Q1W 2/3]</a>	1.0.0	01/09/2022
<a href="#">BR Metastatic - Abraxane [PAClitaxel nanoparticle albumin bound] [Q1W 3/4]</a>	1.0.0	01/09/2022
<a href="#">BR Metastatic - Abraxane [PAClitaxel nanoparticle albumin bound] and aTEZOLizumab</a>	2.0.0	22/04/2022
<a href="#">BR Metastatic - AC [DOXOrubicin and CYCLOPHOSPHamide]</a>	1.0.0	24/03/2022

## Systemic Anti-Cancer Therapy Regimen Library

[Home](#) > [BR Metastatic - Abraxane \[PAClitaxel nanoparticle albumin bound\] and aTEZOLizumab](#) 

BR Metastatic - Abraxane [PAClitaxel nanoparticle albumin bound] and  
aTEZOLizumab

Id: 58481000210105

 Version 2.0.0

Published 22 April 2022

[Send feedback](#)

Treatment overview

Cycle details

Full details

# Pharmacist group

- Started August 2025
- Group of pharmacists who implement regimens from the library.

## Opportunity to:


- Bring practice changes to a forum
- Discuss feedback on regimens
- Share knowledge on electronic prescribing systems



# Cisplatin hydration

## Prior to ACT-NOW:

- Cisplatin hydration duration, volume and type varied significantly.
- No national guidance on hydration.
- Depending on where a patient lived could mean a 2hr appointment or an inpatient stay



## ACT-NOW guidance:

- Consistent hydration across regimens
- Once source with yearly review by supportive care workshop
- Reduced cisplatin hydration time

# Data & analytics

Examples

# When data is mis-aligned

Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan)

Colorectal metastatic **FOLFIRI (modified)** (high dose folinic acid) (fluorouracil leucovorin irinotecan) (05-05)

CRC metastatic - mFOLFIRI [high dose folinic acid] (05-05)

CRC metastatic - mFOLFIRI [low dose folinic acid]

CRC Metastatic - **mFOLFIRI** [low dose folinic acid]

**FOLFIRI**

FOLFIRI (modified)

Gastric and gastroesophageal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) (exclusve)

**IFL (Modified Saltz)**

MCC CRC metastatic - mFOLFIRI [low dose folinic acid]

MCC FOLFIRI

Metastatic Colorectal FOLFIRI

Metastatic Colorectal FOLFIRI 1st Line

mFOLFIRI for advanced colorectal cancer

Neuroendocrine High grade metastatic FOLFIRI (modified) (high dose folinic acid) (fluorouracil leucovorin irinotecan) (04-24)

UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, folinic acid and fluorouracil] [high dose folinic acid] (04-24)

SNOMED makes it easy to align regimens and create coded definitions

Systemic anti cancer therapy regimen (regime/therapy)

Antineoplastic chemotherapy regimen (regime/therapy)

Folinic acid, fluorouracil and irinotecan antineoplastic chemotherapy regimen (regime/therapy)

SCTID: 870249004

870249004 | Folinic acid, fluorouracil and irinotecan antineoplastic chemotherapy regimen (regime/therapy) |

en Folinic acid, fluorouracil and irinotecan antineoplastic chemotherapy regimen (regime/therapy)

en FOLFIRI antineoplastic chemotherapy regimen

en FOLFIRI (folinic acid, fluorouracil, irinotecan) antineoplastic chemotherapy regimen

en Folinic acid, fluorouracil and irinotecan antineoplastic chemotherapy regimen

UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, folinic acid and fluorouracil] [high dose folinic acid]

UGI GAST AND OES Metastatic - mFOLFIRI [irinotecan, folinic acid and fluorouracil] [low dose folinic acid]

CRC Metastatic - mFOLFIRI [irinotecan, folinic acid and fluorouracil] [low dose folinic acid]

CRC Metastatic - mFOLFIRI [irinotecan, folinic acid and fluorouracil] [high dose folinic acid]



# Other ways this data is being used

Patients travel time to receive treatment

Supporting Health NZ

Supporting other agencies (eg: PHARMAC)

Patients with long travel times to systemic anti-cancer therapy treatment centres (2020–2023)

SA3 2023

Number of trips (one-way)



Whanganui



Kāpiti Coast



Eagle Technology, Land Information New Zealand

# Key take aways

- Our aim is to ensure that all New Zealanders receive the best cancer care.
  - We need data to be able to do this.
- Alignment with a regimen is the same: **indication, drug(s), dose, route, frequency (in a cycle), cycle length.**
- The regimen library represents what SACT treatment is prescribed in New Zealand.
  - We welcome feedback and regimen requests.



# Thanks for listening

Contact details:

Katharine.Wakefield@teaho.govt.  
nz